← Back to Search

Cancer Vaccine

DC vaccine for Colorectal Cancer

Phase 1

Waitlist Available

Led By Kim Reiss-Binder, MD

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion (at 12 months)

Awards & highlights

Study Summary

This trial will study if a vaccine is safe and effective in patients with colorectal cancer.

Eligible Conditions

Colorectal Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion (at 12 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion (at 12 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (at 12 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse events experienced by subjects (i.e. safety of DC vaccine in subjects with surgically resected hypermutated CRC)

Changes in numbers of peptide-specific CD8+ T cells (post-vaccine immune response)

Secondary outcome measures

Percentage of CD8+ cells in primary tumor tissue

Side effects data

From 2019 Phase 1 & 2 trial • 64 Patients • NCT02151448

56%

Chills

55%

Anemia

30%

Nausea

30%

Fatigue

25%

Hypoalbuminemia

23%

Headache

22%

Diarrhea

19%

Hyponatremia

19%

White blood cell decreased

19%

Neutrophil count decreased

19%

Fever

17%

Lymphocyte count decreased

16%

Serum amylase increased

16%

Vomiting

16%

Alkaline phosphatase increased

14%

Platelet count decreased

13%

General disorders and administration site conditions - Other, specify

13%

Aspartate aminotransferase increased

13%

Pain

11%

Hypertension

11%

Lipase increased

Abdominal pain

Alanine aminotransferase increased

Blood bilirubin increased

Creatinine increased

Flu like symptoms

Constipation

Weight gain

Hypokalemia

Sinus bradycardia

Colonic obstruction

Flank pain

Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify

Renal and urinary disorders - Other, specify

Respiratory, thoracic and mediastinal disorders - Other, specify

Small intestinal obstruction

Infections and infestations - Other, specify

Ileus

Wound infection

Hepatobiliary disorders - Other, specify

Eye disorders - Other, specify

Urinary tract infection

Thromboembolic event

Heart failure

Catheter related infection

100%

80%

60%

40%

20%

Study treatment Arm

Vaccine + Chemokine Modulatory Regimen

Trial Design

1Treatment groups

Experimental Treatment

Group I: All subjectsExperimental Treatment1 Intervention

All subjects will receive the vaccine and be followed per the schedule of procedures.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

DC vaccine

2014

Completed Phase 2

~110

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor

2,002 Previous Clinical Trials

42,880,995 Total Patients Enrolled

Kim Reiss-Binder, MDPrincipal InvestigatorUniversity of Pennsylvania

1 Previous Clinical Trials

83 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any present openings to join this experiment?

"According to the clinicaltrials.gov listing, this particular medical trial is still open for enrolment and was last edited on February 21st 2022 after being initially posted nearly two years prior."

Answered by AI

Has the DC vaccine been officially sanctioned by the FDA?

"Because the evidence supporting safety and efficacy is still limited, our team at Power gave this DC vaccine a score of 1."

Answered by AI

What is the current enrollment count of this research project?

"Affirmative, clinicaltrials.gov confirms that this research is actively recruiting participants as of February 21st 2022. The trial was initially posted on March 12th 2019 and requires the recruitment of twelve individuals from one medical facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

DC Vaccine in Colorectal Cancer

2019. "DC Vaccine in Colorectal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03730948.